Introduction {#S1}
============

α-Thalassemia is a common genetic disorder that is characterized by deficient or absent synthesis of α-globin chains of the hemoglobin (Hb) molecule.^[@R1]^ The human α-globin gene cluster has two α genes (α2 and α1) on each chromosome 16. A normal person has four functional α-globin genes and is designated as αα/αα.^[@R2]^ Most α-thalassemia determinants are deletions involving one ( --α/αα) or both: loss of either both α-genes from a single chromosome ( - - /αα) or one gene from both chromosomes ( - α/ - α). An individual with three α genes (--α/αα) is not anemic but a heterozygote who inherits two functional α-globin genes (-- --/αα) has mild hypochromic microcytic anemia. Patients with HbH disease inherit only one functional α-globin gene (-- --/--α). They usually produce less than 30% of the normal amount of α-globin. The patients usually have splenomegaly (which may be severe) and occasionally this is complicated by hypersplenism.^[@R1],[@R3]^

Sickle-cell anemia is an autosomal recessive genetic red cell disorder with a worldwide distribution that results from a point mutation at codon 6 of the beta-globin gene, with the replacement of glutamic acid to valine, leading to the production of a defective beta globin chain (β^S^, 6V) of the hemoglobin.^[@R4]^ While the coinheritance of another beta-globin gene anomaly increases the proportion of HbS and therefore the risk of sickling, the combination of a deletion of an alpha-gene anomaly reduces intraerythrocytic HbS concentration, attenuating therefore the problems due to the sickle cell trait.^[@R5]^ Since sickle cell trait is mainly seen in black populations, the coinheritance of HbH disease and a sickle cell trait has only been rarely described.

Usually, in patients with HbH disease, ineffective erythropoiesis in an expanded marrow stimulates iron absorption even if iron stores are adequate, and this stimulation increases the risk of iron excess when transfusions are given.^[@R6]^ We show here a rare case of a coinheritance of a HbH disease together with a sickle cell trait, presenting with iron deficiency.

Case Report {#S2}
===========

A 40-year-old Turkish woman was referred to our outpatient clinic for evaluation and treatment of an undetermined thalassemia and sickle cell trait. The patient suffered from fatigue and splenomegaly. Additionally, she had hepatitis B virus infection most probably transfusion transmitted. The patient has two healthy children.

At first consultation hemoglobin (Hb) was decreased (71 g/L) with microcytosis (MCV 55.1 fL), hypochromia (MCHC 239 g/L), anisocytosis (RDW 20.5 %) and hypochromic reticulocytes (CHr 16.2 pG) ([Table 1](#T1){ref-type="table"}). Leucocyte and platelet counts were within the normal range. On the blood smear we found anisocytosis, poikilocytosis, anisochromia, microcytes and target cells. The patient had severe iron deficiency (ferritin level 7 ng/mL; transferrin saturation 7%). In brilliant cresyl blue staining more than 50% of the erythrocytes showed typical HbH inclusions. The sickle cell test was positive. HPLC (High-performance liquid chromatography) revealed a normal HbA~2~ (2.3%) and HbF (0.7%), an abnormal hemoglobin S (19%) and persistence of HbA (\>50%) ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Genomic DNA was isolated using manual or automated extraction protocols. Using a reverse-hybridization of biotinylated PCR products (ViennaLab) a heterozygous mutation of the β gene at codon 6 (HBB:c.20A\>T; corresponding to HbS), was detected. The α-globin genes were amplified by PCR and sequenced using the BigDye™ Terminator Cycle Sequencing Kit, and the ABI 3130 automated capillary sequencer (Applied Biosystems Inc., Foster City, CA, USA). We revealed a 5 nucleotide deletion in the IVS-I donor site (GAGGTGAGG\>GAGG\-\-\-\--) of the α2-globin gene ([Figure 2](#F2){ref-type="fig"}). This deletion was pseudo-homozygote since we showed later that one allele of the alpha gene complex contained a 6.1kb deletion eliminating both alpha genes. Multiplex Ligation-dependent Probe Amplification (MLPA) reactions were performed for detection of copy number variation in the α-globin gene clusters. The reaction was performed according to the manufacturers protocol using the SALSA MLPA kit P140B2 HBA and the ServiceXS HBA kit described by Harteveld *et al.*, 2005.^[@R7]^ Products were separated by capillary electrophoresis on the ABI 3130 (Applied Biosystems) and data analysed using GeneMarker (SoftGenetics). Threshold ratios for deletion and duplication were set at \>0.75 and \>1.3, respectively. We found a heterozygous deletion of probes 5--25 with the P140B2 kit and of probes 8--15 with the ServiceXS kit. This corresponds to a more than 6.1kb long deletion of one allele in the alpha gene complex including the zeta and both alpha genes, leaving the theta gene intact. This type of deletion is called - - Med-II and is rather common in the Mediterranean area and was frequently found in the Turkish/Greek population.^[@R8]^

Table 1Hematological data from the patient.Parameter, UnitsAt 1^st^ presentation3 months after 1500 mg Ferric carboxy-maltose infusionReference valuesHb, g/L7183120--160HCT, L/L0.300.330.36--0.46MCV, fL55.155.179--95MCH, pG13.213.727.0--33.2MCHC, g/L239250320--360hypoRBC, %76.169.8\<5.0RDW, %20.519.911.5--14.5Platelets, ×10^9^/L214162150--450Reticulocytes, ‰202210--27Reticulocytes, ×10^9^/L10811240--140WBC, ×10^9^/L4.856.023.50--10.00Neutrophils, ×10^9^/L3.424.381.300--6.700Ferritin, ng/mL73310--200Transferrin saturation, %71416--45%sTR, mg/L23.1111.642.2--4.5[^3]

Table 2Quantitave values of hemoglobin components from the patient obtained by High-performance liquid chromatography and results of molecular analysis.ParameterValueReferencesHb A~2~, %2.32.0--3.5Hb F,%0.7\<2Hb H, %110Abnormal HbHbSNonePerc. abnormal Hb, %190Sickle cell testPositiveNegativeMutation analysis1.α2 IVS-I donor site −5nt / \-- MED II deletion2. heterozygous Hb S (HBB:c.20A\>T)[^4]

Figure 1High-performance liquid chromatography pattern of our patient with Hemoglobin H (HbH) disease. Red graph represents our patient with clear HbH/HbBart\'s peak at 1.5 minutes and a HbS peak at 11 minutes retention time. Blue graph is a control.

Figure 2Sequence of the alpha 2 gene. Hemizygote deletion of 5 nucleotides at the IVS-I donorsite of the alpha2 gene, HBA2:c.95+2_95+6delTGAGG.

Thus this patient suffers from HbH disease and a sickle cell trait; the HbH disease was due to an α^0^-thalassemia (- -Med-II) / α^+^-thalassemia (α2 IVS-I donor site −5nt). The symptomatic anemia with iron deficiency was treated with iron infusion with a total dose of 1500 mg ferric carboxy-maltose. Thereafter, the Hb levels increased up to 83 g/L, the ferritin level to 33 µg/L and the transferrin saturation to 14% ([Table 1](#T1){ref-type="table"}).

Discussion {#S3}
==========

We show here a patient with a rare hereditary constellation of three different genetic anomalies of the haemoglobin genes: the patients presented HbH disease with two deletions on the alpha genes and a sickle cell anomaly on the beta gene. The coinheritance of HbH and sickle cell trait is rare.^[@R9]^ There are only few published case reports about the coincidence of HbH disease with a \-- MED II deletion and a Hb S heterozygosity.^[@R10]--[@R11]^

HbH disease is a severe form of α-thalassemia but is compatible with life. Patients with HbH disease have a severe hypochromia with low MCV and MCH values, but increased iron stores.

In our case, the moderate, microcytic hyochromic anemia and the splenomegaly were the consequences of the HbH disease, and could not be reversed by iron substitution. However, we assume that the structural beta-globin chain variant in our patient leads to lower quantities of unstable HbH, and therefore to a milder form of HbH disease with less ineffective hematopoiesis and only minimal increase of gastrointestinal iron absorption. Hypermenorrhoea and two pregnancies were additional reasons for the unusual iron deficiency in this case of thalassemia.
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